Hologic, Inc. is primarily engaged in healthcare solutions focusing on women's health. Although the company displays a steady growth potential in diagnostics and imaging, the stock's valuation metrics warrant a cautious approach due to the current market conditions.
The fundamental rating for Hologic, Inc. presents a balanced scorecard, emphasizing its strengths in certain financial aspects, while also highlighting potential risks.
Category | Score | Visualization |
---|---|---|
Discounted Cash Flow | 5 | |
Return On Equity | 4 | |
Return On Assets | 4 | |
Debt To Equity | 2 | |
Price To Earnings | 1 | |
Price To Book | 2 |
Recent historical data indicates a consistent rating over the past period, with a noticeable mention of past achievements.
Date | Overall Score | DCF | ROE | ROA | D/E | P/E | P/B |
---|---|---|---|---|---|---|---|
2025-09-03 | 3 | 5 | 4 | 4 | 2 | 1 | 2 |
Historical | 0 | 5 | 4 | 4 | 2 | 1 | 2 |
Analyst price targets suggest a promising outlook with measured optimism, reflecting both high and median expectations.
High | Low | Median | Consensus |
---|---|---|---|
$75 | $65 | $70 | $70 |
The sentiment among analysts highlights a predominantly positive stance, with an emphasis on buy recommendations.
Recommendation | Count | Visualization |
---|---|---|
Strong Buy | 0 | |
Buy | 23 | |
Hold | 18 | |
Sell | 1 | |
Strong Sell | 0 |
Hologic, Inc. demonstrates solid performance in various financial metrics adhering to a generally favorable analyst sentiment. However, some valuation metrics suggest potential overvaluation, which introduces a level of risk. The consistent historical performance underscores stability in operations, balanced by future opportunities in diagnostics and imaging expansion. Investors should weigh these factors against current market volatility. Overall, Hologic remains a viable option for those focused on the healthcare sector.